ImmunoMet is a clinical stage biotech utilizing cellular metabolism to develop novel anti-tumor and immune-metabolism therapies. ImmunoMet was founded in 2015 as a is Spin-off from HanAll Biopharma, a mid-sized Korean pharma co, and is headquartered at Houston JLABs near MD Anderson. We have raised $20 M post spin-off including $10 M from VCs. Our lead molecule, IM156, is an OXPHOS inhibitor which has demonstrated impressive in vivo efficacy in resistant solid tumors and entered Phase 1 in 4Q17. ImmunoMet owns a large biguanide library which forms an engine we are leveraging to unlock value and develop products in immuno-metabolism.